

# Public Participation in Decision-Making on the Coverage of New Antivirals for Hepatitis C

## Abstract

### Purpose

New hepatitis C medicines such as sofosbuvir underline the need to balance considerations of innovation, clinical evidence, budget impact and equity in health priority-setting. This article examines the role of public participation in addressing these considerations.

### Design/Methodology/Approach

The article employs a comparative case study approach. It explores the experience of four countries—Brazil, England, South Korea and the USA—in making coverage decisions about the antiviral sofosbuvir and involving the public and patients in these decision-making processes.

### Findings

Issues emerging from public participation activities include the role of the universal right to health in Brazil, the balance between innovation and budget impact in England, the effect of unethical medical practices on public perception in South Korea, and the legitimacy of priority-setting processes in the USA. Providing policymakers are receptive to these issues, public participation activities may be reconceptualized as processes that illuminate policy problems relevant to a particular context, thereby promoting an agenda-setting role for the public.

### Originality/Value

The article offers an empirical analysis of public involvement in the case of sofosbuvir, where the relevant considerations that bear on priority-setting decisions have been particularly stark. The perspectives that emerge suggest that public participation contributes to raising attention to issues that need to be addressed by policy-makers. Public participation activities can thus contribute to setting policy

1  
2  
3 agendas, even if that is not their explicit purpose. However, the actualization of this  
4  
5 contribution is contingent on the receptiveness of policymakers.  
6  
7

## 8 **Keywords**

9  
10 Hepatitis C, direct-acting antivirals (DAAs), sofosbuvir, public and patient  
11 involvement (PPI), priority-setting, agenda-setting  
12  
13  
14

## 15 **Article Classification**

16 Case Study  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55

## Introduction

In 2013 the Food and Drug Administration (FDA) in the United States of America (USA) approved sofosbuvir and simeprevir for the treatment of chronic hepatitis C infections (FDA, 2014). The regulatory agencies of other countries soon followed and the use of sofosbuvir was approved by the European Medicines Agency (EMA) in January 2014 (EMA, 2015). These medicines, along with a third called daclatasvir, were hailed as a breakthrough in the treatment of patients with chronic hepatitis C as they are considered to be highly effective antiviral agents that, for the first time, attack the hepatitis C virus (HCV) directly. These drugs are not only more effective in achieving sustained virological response—effectively curing patients—but also have fewer side effects than previous treatments. Unsurprisingly, there has been high demand for these new “cures” for hepatitis C among patients—especially given the alternative prospects of deteriorating liver function and possible liver transplantation or death, alongside the psychological distress and social stigma attached to the disease (Vietri et al, 2013; Younossi and Henry, 2015).

However, the new HCV medicines come at a price. It is a price that most countries struggle to afford, regardless of their wealth or the structure of their health system. The actual price of the regimen is hard to unveil because many health care systems engage in confidential negotiations with pharmaceutical manufacturers for discounted prices, but a 12-week treatment with sofosbuvir has been estimated to cost as much as \$84,000 in the USA (McCarthy, 2015). Policymakers or insurers face difficult decisions on whether to cover these novel and costly medicines, weighing the benefits these drugs could offer against the opportunity costs of securing health benefits for the broader population. Such challenges raise questions about what role, if any, patients and the public have in priority-setting decisions for new and expensive drugs. This article outlines how the highly innovative, but very expensive, new hepatitis C medicines have exacerbated the challenge of making prioritization decisions in health care and explores the role of patient and public involvement (PPI) in addressing this challenge.

The focus of the article arises from deliberations held at a workshop at the Brocher Foundation in Switzerland in November 2015. The workshop was dedicated to exploring ways to improve equitable access to health care through increasing public and patient involvement in prioritization decisions. It brought together

academic and policy experts in health priority-setting and public involvement from 12 countries. Its purpose was to exchange knowledge and observations about country experiences of PPI in priority-setting. One of the observations emerging from the deliberations was that the new HCV medicines seem to have exacerbated the challenge of making fair prioritization decisions because of the complex set of issues around innovation, clinical evidence and budget impact to which they give rise. This article asks what role, if any, public involvement has played in alleviating some of these issues. How have countries involved the public and patients in addressing the question of how to secure equitable access to new hepatitis C medicines? What can we learn from this experience?

In the extant literature, the importance of involving the public in health priority-setting is explained with reference to the complex and multiple relevant considerations that can bear on decisions. For example, to justify the model of “accountability for reasonableness”, Daniels and Sabin (1997) argue that priority-setting institutions must ensure fair processes. Because more than one relevant consideration generally bears on priority-setting questions, relevant considerations often conflict and there is no consensus among decision-makers, commentators or the public at large as to how to trade them off against each other. Daniels and Sabin give PPI a role in ensuring fair process and many commentators argue that it should take center-stage (Emanuel, 2002; Friedman, 2008; Rid, 2009; Sabik and Lie, 2008).

This article contributes to the existing debates by offering an empirical analysis of public involvement in the case of sofosbuvir, where the relevant considerations that bear on priority-setting decisions have been particularly stark. It examines how the public has been involved in decisions on new HCV medicines in four countries (Brazil, England, South Korea and the USA), thereby offering comparative insights on how different health systems involve the public in complex priority-setting problems, and on the perspectives that emerge. Perspectives that emerge include the role of the universal right to health in Brazil, the balance between innovation and budget impact in England, the effect of unethical medical practices on public perception in South Korea, and the legitimacy of priority-setting processes in the USA. Although these issues are contextual and not necessarily novel in the individual contexts, they appear more pronounced in the case of sofosbuvir. If policymakers are aware of, and receptive to, these issues, public participation activities may be usefully re-conceptualized as processes that illuminate salient policy

1  
2  
3 problems relevant to a particular context, thereby supporting an agenda-setting role  
4  
5 for the public. The actualization of this role is highly contingent on policymakers  
6 being receptive to the issues. Given the important perspectives that emerged in the  
7  
8 case of sofosbuvir, this article concludes that further research is necessary on whether  
9  
10 they have found traction in the public policy arenas of Brazil, England, South Korea  
11 and the USA.  
12

13 The article proceeds by providing a brief conceptual overview of health  
14  
15 priority-setting and PPI, the methods and data for the case studies, the new HCV  
16 medicines generally, and of sofosbuvir particularly. These sections set the scene for  
17  
18 the discussions of the country case studies and the conclusion in the latter parts of the  
19  
20 article.  
21

## 22 **Health Priority-Setting and Patient and Public Involvement**

23

24  
25 Setting priorities in health care holds a prominent place on the policy agenda  
26  
27 in countries around the world, particularly as countries seek to achieve universal  
28  
29 health coverage. The advent of this agenda, including the creation of health  
30  
31 technology assessment (HTA) organizations, has brought about an increased interest  
32  
33 in the role of PPI in health prioritization (e.g. Martin et al., 2002; Abelson et al.,  
34  
35 2007) because decisions involve making difficult choices that cannot be made solely  
36  
37 on technical grounds and hence need to be justified and legitimized in the context of  
38  
39 social values and procedural justice (Clark and Weale, 2012; Daniels and Sabin,  
40  
41 1997).

42 Regardless of where priority-setting takes place, it is concerned with making  
43  
44 decisions that provide a good quality, and a fair, health service while ensuring that the  
45  
46 health system is sustainable. The extant literature suggests that public input into the  
47  
48 choices made should be included as one important criterion against which to assess  
49  
50 the fairness of prioritization decisions (Sibbald et al., 2009; Kipiriri and Martin, 2010;  
51  
52 Sabik and Lie, 2008). However, barriers to public involvement exist (Goold et al.,  
53  
54 2005) and little empirical evidence is available on the effect of PPI generally, and  
55  
56 different modes of PPI such as deliberative processes specifically (Mitton et al., 2009;  
57  
58 Abelson et al., 2003).  
59

60 This article follows Weale et al.'s (2016, p. 5) definition of public  
participation in priority-setting as involving "[...] individuals or groups taking part in

processes of policy making that shape the determination of priorities in health care and the conditions of access of different groups in society”. It is collectively-orientated and excludes forms of patient involvement such as involvement in research or shared decision-making as these forms of involvement are not aimed at bringing about a decision that affects public policy at large. This collectively-orientated mode of public participation can come in different forms such as the inclusion of patient or public representatives in HTA bodies, mini-publics or consultative forums convened to garner public and patient views. Importantly, it also includes more unconventional forms of public participation such as protests, demonstrations, public campaigns and litigation. To include these forms of involvement is crucial because in some countries they have become a routinized mode of involvement that can affect priority-setting decisions (Weale et al., 2016; Slutsky et al., 2016).

## Methods and Data

The article employs a comparative case study approach. Its main units of analysis are the country-specific processes of public participation in the case of sofosbuvir. We focus on sofosbuvir because it has received substantial attention in media outlets worldwide. The country case selection was informed by the aim to include countries with conventional and unconventional modes of public participation in health prioritization (Weale et al., 2016). For reasons of data availability, the selection was restricted to the countries represented at the Brocher Foundation workshop entitled “Improving equitable access to health care through patient and public involvement in prioritization decisions” in Switzerland in November 2015. The represented countries were Australia, Brazil, China, Colombia, Germany, New Zealand, South Africa, South Korea, Sri Lanka, Thailand, the United Kingdom (UK) and the United States of America (USA).

Following Slutsky’s et al.’s (2016) distinction between consensus, i.e. conventional, and contestatory participation, i.e. unconventional, modes of participation, Brazil, England, South Korea and the USA were selected as cases. England represents a system where contestatory participation is not routinized (Slutsky et al., 2016), whereas Brazil and South Korea represent countries where it is routinized. The USA represent a unique case in that participation is neither clearly consensus nor contestatory-based because of a lack of federal prioritization decision-

1  
2  
3 making in which the public participates in a routine fashion. Nevertheless, as we shall  
4  
5 see, forums for participation do exist in the form of institutes such as the Institute for  
6 Clinical and Economic Review (ICER).  
7

8 The article draws on country data on PPI and health priority-setting that was  
9  
10 presented at the Brocher Foundation workshop. This data was supplemented by data  
11 from secondary literature. At the workshop policy and academic experts presented the  
12 status quo of health priority-setting and PPI in their countries following a template of  
13  
14 nine areas (see <http://www.ucl.ac.uk/socialvalues> for presentations):  
15

16 1) Overview of health system and approaches to prioritization;  
17

18 2) Degree and nature of PPI in prioritization;  
19

20 3) Rationale for PPI;  
21

22 4) Successes and challenges;  
23

24 5) A prioritization case study and impact of PPI in this case;  
25

26 6) Issues highlighted by the case study;  
27

28 7) Ethical or social values questions in relation to PPI;  
29

30 8) Lessons learnt;  
31

32 9) Future plans for PPI in prioritization.  
33

34 In its discussion of the country cases, this article broadly follows the outlined  
35 template. Each case study begins with a brief overview of the health system and  
36 approaches to PPI in health prioritization. A discussion of the rationale as well as the  
37 successes and challenges of PPI is omitted because the focus is on the prioritization  
38 case study (sofosbuvir) and the issues, ethical questions and lessons learnt. Unless  
39 they emerge directly from PPI in the case of sofosbuvir, the category of future plans  
40 for PPI is also omitted for the purpose of this paper.  
41  
42  
43  
44

45 Due to the small number of cases included in this article, the generalizability  
46 of the observations is limited. However, the purpose of this article is not to bring forth  
47 generalizable claims, but to provide an insight into the role PPI has played in  
48 coverage decisions on new HCV medicines. This is to gain a better understanding of  
49 the contributions of PPI activities in complex prioritization decisions.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## New HCV medicines

“Hepatitis C is a virus that can infect the liver” (NHS Choices, 2015). Long-term, and potentially life-threatening complications from chronic hepatitis C infection include liver cirrhosis and liver cancer. More than 185 million people are affected by hepatitis C and approximately 350,000 people die each year as a consequence (WHO, 2014, p. 25). Hepatitis C is transmitted through contact with infected blood specimens (WHO, 2014). There are several types and subtypes of the infection, so-called genotypes.

In recent years a rapid development in treatments for chronic hepatitis C has taken place. In 2011 and 2012 the medicines telaprevir and boceprevir were introduced. Since 2013 additional medicines have been approved around the world, namely sofosbuvir, simeprevir and daclatasvir. These medicines are direct-acting antivirals (DAAs) that target the HCV itself, an innovation over previous treatments that indirectly suppressed the virus through inhibiting its replication.

This article focuses on sofosbuvir. The main clinical endpoint measured in randomized controlled trials (RCTs) on hepatitis C medicines is the sustained virological response (SVR), that is the virus being undetectable in the blood three or six months after treatment (WHO, 2014). Sofosbuvir achieved a SVR in over 90% of the patients across different genotypes of hepatitis C (WHO, 2014). Clinical experts equate the achievement of a SVR to a cure (NICE, 2015, p. 46). Arguably, providing a drug like sofosbuvir would not only yield benefits for patients, but also avert future high costs associated with liver transplants as well as generate public health benefits through reduced HCV transmission. However, there is still much uncertainty surrounding the potential of future (liver) complications for patients who have cleared the virus or the question of which patients would progress to more serious stages of liver disease if left untreated. Trials on sofosbuvir report fewer, and less severe, side effects as well as a potential reduction of the treatment cycle from 24-48 weeks to as little as 12 weeks (WHO, 2014). Additionally, sofosbuvir is administered orally in the form of a pill once a day for usually 12 weeks, whereas previous methods of administration were mostly through injections.

However, at an estimated price of \$84,000 for a 12-week treatment in the USA, sofosbuvir has been labeled the \$1,000 pill (McCarthy, 2015). The first WHO guidelines on the screening, care and treatment of patients with hepatitis C



1  
2  
3 recommend access to the new medicines. In the absence of sufficient funds to treat the  
4  
5 entire patient population, they recommend to treat the sickest patients first (WHO,  
6 2014). This is the way a number of countries have approached the access, for example  
7  
8 guidelines in the USA and England recommend to treat patients with cirrhosis first  
9  
10 (McCarthy, 2014; NICE 2015).

11 The challenge of providing access to these new medicines includes  
12 considerations of cost effectiveness, affordability, health equity, public health and the  
13  
14 ethical implications of treating the sickest patients first. One of the biggest issues is  
15 how to resolve the perceived tension between cost effectiveness and affordability. The  
16  
17 approach to prioritization in many tax-based health systems focuses on the assessment  
18  
19 of cost effectiveness, with an assumption - explicit or implicit - that treatments should  
20 be made available to all patients for whom they deliver outcomes whose cost  
21  
22 effectiveness exceeds a pre-determined threshold. But when the total budget impact of  
23  
24 such a treatment is large, its adoption may require significant re-direction of  
25  
26 resources, either from other areas of health spending, and/or from areas of non-health  
27  
28 expenditure (Claxton et al., 2015; Ward, 2015). A re-direction of resources raises  
29  
30 questions of equity with regard to the patient groups who lose out as a result. It  
31 therefore requires debate and resolution in the political space, which may or may not  
32  
33 include the wider public.  
34

35 The above issues are complicated by the fact that Hepatitis C is already  
36 strongly associated with health inequities. It disproportionately affects populations in  
37  
38 low and middle income countries (Graham and Swan, 2015), which to date have not  
39  
40 had much access to available treatments due to the challenging screening and  
41  
42 monitoring requirements. Moreover, sofosbuvir and other DAAs have been labeled a  
43  
44 cure, a label that few other medical innovations achieve. Familiar issues of pricing  
45  
46 and the current patent system are also surfacing. For example Argentina, Brazil,  
47 China, Russia and the Ukraine are challenging the current patent for the new hepatitis  
48  
49 C drugs (Bagcchi, 2015). Similarly, a non-governmental organization of doctors in  
50  
51 France that provides healthcare for vulnerable populations worldwide, the Médecins  
52 du Monde, is challenging the patent at the European Patent Office (EPO) (Boseley,  
53 2015). Given this mix of complex issues, the question arises if PPI can help  
54  
55 adjudicate between the different issues. What has the experience of involving the  
56  
57 public and patients been in the case of sofosbuvir?  
58  
59  
60

## Public Participation in the Case of Sofosbuvir

### *Brazil*

The Brazilian Public Health System, better known by the acronym SUS (Sistema Único de Saúde; Unified Health System) was established under the Federal Constitution of Brazil in 1988. Enshrined in the Constitution is a right to health care and a governmental duty to guarantee universal and equal access to services and activities that promote, protect and restore health (Paim et al., 2011). Brazil's forums for public participation include municipal and state health councils comprised of members of the public and patient representatives. Through these councils health care planners are held to account by the citizenry (Dall'Agnol Modesto et al., 2007). Brazil's tradition of public involvement is also reflected in the way the public is involved in the SUS. The National Health Council, which consists of a mix of representatives of service user organizations (50%), health care worker representatives (25%), government and health service providers (25%), holds monthly meetings in which proposals are deliberated (Dall'Agnol Modesto et al., 2007).

In the case of sofosbuvir, the National Commission on Technology Incorporation in the National Health System (CONITEC), the HTA body in Brazil, decided unanimously to recommend the inclusion of sofosbuvir, daclatasvir and simeprevir for the treatment of chronic HCV (CONITEC, 2015). The recommendation was preceded by a public consultation on HTA report. Public contributions were made through submissions to the CONITEC website.

During the process of assessing sofosbuvir, CONITEC also presented revised Clinical Protocol and Therapeutic Guidelines (PCDT) for the disease, with new guidance on treating the condition. The assessment process did not evoke as much public protest and engagement as did the revised PCDT. According to the revised protocol, the degree of fibrosis determines the group of patients who are eligible to be treated with the new antiviral agents under the SUS, excluding patients at fibrosis stages F1 and F2 (PCDT, 2015).

The Brazilian Movement of the Fight against Viral Hepatitis voiced its dissatisfaction with the protocol and invoked the constitutional universal right to health, claiming that the patient groups included in the protocol "represent less than 4% of the current need and means tearing the principle of universality of access to

health”<sup>1</sup> (MBHV, 2015). The official estimate is that 60,000 patients will be treated with sofosbuvir in the next two years. To the Work Group of Intellectual Property (GTPI), “this is less than 1/3 of the related demand [...]” (GTPI, 2015).

The fact that the Brazilian Movement of the Fight against Viral Hepatitis invoked the constitutional universal right to health reflects a prominent feature of many health systems in Latin America where the right to health is enshrined in the Constitution. Reimbursement decisions on medicines are made through benefit plan assessments (BPA), following the principles of financial sustainability and of clinical efficiency. For a molecule to be considered for BPA, it generally has to overcome the HTA hurdle. In order to ensure financial sustainability some countries perform different degrees of Budget Impact Analysis (BIA) (e.g. Ministerio de Salud de Colombia, 2015). In this setting there is an inherent tension between the HTA results and the BPA results that may yield that a cost effective technology is unaffordable for the entire system, which is why CONITEC recommended restricting access to sofosbuvir according to fibrosis stage.

Given the constitutional protection of the right to health, Latin American individuals and campaign groups can resort to courts to challenge the results of the HTA and BPA. Every year thousands of Latin Americans resort to this unconventional form of PPI and more often than not judges rule in favor of the avalanche of plaintiffs (Cubillos et al., 2012). The effect that easy litigation has on the incentives to participate in the more established PPI mechanisms is unclear. If one can almost certainly win a case in less than two weeks, why join a process that may take months or years and that may not lead to your desired outcome? Policymakers in Latin America continue to grapple with the constraining effects of the constitutional right to health on priority-setting decisions.

### *England*

The National Health System (NHS) is a tax-based health system in which national and local structures share decision-making responsibility. At local level, 211 clinical commissioning groups (CCGs) are responsible for commissioning (Thorlby and Arora, 2014), i.e. buying, health services from public, private or non-profit health

---

<sup>1</sup> Translated by one of the authors of this article.

1  
2  
3 care providers. At the national level, NHS England oversees spending and allocation  
4  
5 of resources (NHS England, 2016). CCGs and NHS England are supported by the  
6 National Institute for Health and Care Excellence (NICE), an organization responsible  
7  
8 for appraising the clinical and cost effectiveness of new medicines. If NICE makes a  
9  
10 positive recommendation on a new drug, then commissioners are under a legal  
11 obligation to make the treatment available (NICE, 2016). NICE makes its appraisals  
12  
13 on the basis of clinical and cost effectiveness considerations as well as social value  
14  
15 judgements (Rid et al., 2015).

16 NICE conducts a public consultation process for every treatment it appraises.  
17  
18 In this process there are two groups that are allowed to participate, namely consultees  
19  
20 and commentators. Consultees include patient and professional organizations, the  
21 pharmaceutical manufacturer, government and NHS entities (NICE, 2013, p. 4).  
22  
23 Commentators include manufacturers of comparator technologies or research groups  
24  
25 who are allowed to comment, but do not have a right to appeal the decision. The  
26 wider public can submit comments on NICE's website (NICE, 2016a).  
27

28 NICE made a positive recommendation for the use of sofosbuvir, although the  
29  
30 use of sofosbuvir in genotypes 4, 5 and 6 was only recommended in patients whose  
31 infection had already progressed to liver cirrhosis (NICE, 2015). The contentious  
32  
33 issues did not arise as a result of NICE's appraisal of sofosbuvir, but as a result of  
34  
35 NICE's decision to grant NHS England an extension to the normal implementation  
36 period in which a NICE-recommended treatment has to be made available on the  
37  
38 NHS. Usually NHS commissioners have to ensure that patients receive access to the  
39  
40 recommended treatment within three months after it has been recommended (NICE,  
41 2016). In the case of sofosbuvir a waiver of this period was sought by NHS England  
42  
43 (NICE, 2014a). Four reasons were provided: First, NHS England argued that the  
44  
45 health service had to be reworked in order to provide access to the new medicines  
46 through specialized treatment centers. Second, a substantial increase in demand for  
47  
48 treatment could be expected, making it necessary for NHS England to ensure it could  
49  
50 accommodate this demand. Third and fourth, networks for service provision would  
51 have to be created in order to guarantee that appropriate screening and monitoring  
52  
53 structures were in place for hepatitis C patients (NICE, 2014a).  
54

55 Although NHS England's request downplayed the expected budget impact of  
56 sofosbuvir as a reason for the request—because budget impact is not an eligible reason  
57  
58 for such extensions under the legal framework set by the government—the ensuing

1  
2  
3 protest suggests that stakeholders agreed that it was a veiled request based on  
4  
5 concerns about budget impact (NICE, 2014b). The submissions by NHS England  
6 suggest that such views were not far-fetched. According to NHS England's  
7 submission: "[...] at the prices proposed by the manufacturer in their NICE  
8 submission, this technology is not affordable at the quantum of new expenditure it  
9 would represent" (NICE, 2014, p. 8). Consultees were given the opportunity to  
10 comment on NHS England's request. One patient organization summarized the  
11 problems as follows:  
12  
13  
14

15 The Hepatitis C Trust objects in the strongest possible terms to any attempt to  
16 introduce budget as a factor. If we are going to change our health care  
17 resource allocation model to one based on arbitrary consideration of this  
18 year's budget, then this should be debated nationally, preferably through an  
19 election manifesto. Either NICE has a mandate to decide resource allocation  
20 or it doesn't (The Hepatitis C Trust, 2014, p. 6).  
21  
22  
23  
24

25 The submissions in response to NHS England's request to delay the date by  
26 which sofosbuvir has to be made accessible highlights complex questions about the  
27 how the ability of NICE's decision-making framework to accommodate cost  
28 effectiveness and affordability is perceived by stakeholders. The patient  
29 representatives raised the issue that if budget impact is an implicit consideration in  
30 cases such as sofosbuvir, then this has to be made explicit and deserves debate in the  
31 wider public and political policymaking arena.  
32  
33  
34  
35  
36  
37

### 38 *South Korea*

39  
40  
41

42 The Republic of Korea has a National Health Insurance Service (NHIS) that  
43 covers 96.6% of the population (OECD, 2012). The rest of the population is covered  
44 "[...] by a medical aid plan which is directly funded by [...] the national and local  
45 governments [...]" (Ahn, 2012, p. 344). While the NHIS is known for its population-  
46 based universal coverage, the benefits that are covered are limited and out-of-pocket  
47 payments were at 36.9% in 2013 (OECD, 2015) even though the benefit coverage has  
48 expanded since the 1990s.  
49  
50  
51  
52

53 In 2012 the NHIS set up a lay citizen's council, the Citizen Committee for  
54 Participation, made up of lay members of the public who are selected following an  
55 application process. Although still in its early years, the decision-making mechanism  
56 of the Committee, and its influence on the final decisions by the Health Insurance  
57  
58

1  
2  
3 Policy Committee (HIPC), are considered significant. In its first year 69% of newly  
4  
5 covered services were originally chosen and recommended by the Citizen Committee  
6 (Oh et al., 2015). However, except for the Citizen Committee, PPI is not prominent in  
7  
8 Korea unless a nationwide interest develops that puts pressures on adopting new  
9  
10 health technologies, especially pharmaceuticals. Such was the case with sofosbuvir.

11 The case of sofosbuvir reached the public agenda not through the Citizen  
12  
13 Committee, but through a scandal that rocked a clinic in Seoul in November 2015.  
14  
15 Sofosbuvir was approved by the regulatory authority in September 2015 (MFDS,  
16 2015). A scandal arose in a neighborhood in Seoul when an outbreak of HCV was  
17  
18 tied to the re-use of disposable needles at a local clinic specializing in intravenous  
19  
20 (IV) injection services (Ah-young, 2015). According to the Korea Times (Ah-young,  
21 2015a), a total of 78 HCV infections were confirmed until the fourth of December  
22  
23 2015 and 55 out of 78 patients were found to have type 1a, which is usually prevalent  
24  
25 in less than 1% of the hepatitis C patients in Korea (Seong et al., 2013). Many  
26  
27 Koreans learned about the disease and the treatment option of sofosbuvir and its  
28  
29 combination drug from news reporting on a massive scale and they were sympathetic  
30  
31 to the victims of unethical medical practices. The incident elevated the issue of  
32  
33 sofosbuvir to the national political arena, with public and advocacy groups  
34  
35 campaigning for access to the new medicines. The coincidence of this event and the  
36  
37 reimbursement review process of these drugs finally resulted in the Ministry of Health  
38  
39 and Welfare asking for a faster review of sofosbuvir (The DailyPharm, 2015).

40 The Korean experience highlights additional ethical issues that characterize  
41  
42 the debate on new hepatitis C drugs, namely issues of fairness, government  
43  
44 accountability and public responsibility when infections occur due to unsafe medical  
45  
46 practices. This is the case in the recent scandal in Korea, but similar examples can be  
47  
48 found in other countries, for example in the UK where contaminated blood  
49  
50 transfusions in the 1980s led to increased HCV infections. Even though this issue did  
51  
52 not emerge as a result of formalized PPI processes, the public outcry in Korea  
53  
54 underlines the effectiveness of public campaigns in the face of such scandals. The  
55  
56 final reimbursement decision is outstanding at the time of writing, but given the  
57  
58 scandal and the ensuing public reaction, it is unlikely that the formalized PPI process,  
if pursued by the decision-making authorities, will lead to any recommendation other  
than to reimburse sofosbuvir.

7 Due to the fragmented nature of the American health care system there is no  
8 one government-mandated institution for health priority-setting. Following the  
9 introduction of the Patient Protection and Affordable Care Act in 2010, the health  
10 care system remains a predominantly private system but the percentage of uninsured  
11 continues to drop (The Commonwealth Fund, 2015). There are two publicly  
12 subsidized and federally managed health care programmes, namely Medicare for the  
13 elderly population over 65 and Medicaid for families meeting low-income eligibility  
14 criteria (The Commonwealth Fund, 2015). Given the lack of institutionalized priority-  
15 setting, this section examines the experience of an independent research body, the  
16 Institute for Clinical and Economic Review (ICER)<sup>2</sup>, that produces evidence reports  
17 on new medicines, on which payer organizations such as insurers draw.  
18  
19

20  
21 The Institute for Clinical and Economic Review is an independent research  
22 institute funded largely by non-profit foundations. It produces evidence reports on  
23 medical technologies to help guide the application of evidence to clinical practice and  
24 insurance coverage policy (ICER, 2014). The Institute has created  
25 regional committees of independent clinicians and public representatives, called  
26 Comparative Effectiveness Public Advisory Councils (CEPAC), who are convened to  
27 deliberate on evidence reports in meetings open to the public (ICER, 2016). The  
28 meetings are spent debating the evidence, after which the CEPAC votes on whether  
29 the evidence is adequate to demonstrate that a new technology is as good or better  
30 than other options available to patients. The reports include evidence on cost  
31 effectiveness and potential budget impact and the Institute asks the CEPAC groups to  
32 vote on the "value" of new interventions.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 The Institute's draft evidence report on the HCV medicines received criticism  
46 from patient advocacy groups focused predominantly on the results of the economic  
47 analyses that found that these drugs would not reduce long-term costs in the health  
48 care system while presenting huge potential short-term costs that could overwhelm  
49 health care budgets (ICER, 2014a). At the public CEPAC meeting, the CEPAC voted  
50 that the evidence was adequate to demonstrate the clinical superiority of the new  
51  
52  
53  
54

55  
56 <sup>2</sup> In order to avoid confusion between the incremental cost effectiveness ratio (ICER) and the  
57 Institute for Clinical and Economic Review (also ICER), this article does not use the 'ICER'  
58 abbreviation for the Institute, but refers to it as the 'Institute' or spells out its full name.

1  
2  
3 drugs but that they represented a "low" value to the health care system<sup>3</sup> (ICER,  
4  
5 2014b). The voting stage of the meeting was followed by a so-called policy  
6 roundtable, an invited group composed of representatives from insurers,  
7  
8 manufacturers, clinical experts and patients. The roundtable included the leader of one  
9  
10 of the patient groups. This representative criticised the vote of the CEPAC and sought  
11 to cast aspersions on the clinical expertise, primary motives, and financial interests of  
12  
13 all involved (ICER, 2014c). The clinical experts responded by expressing their belief  
14  
15 that, for clinical and economic reasons, the most reasonable path forward was to  
16 prioritize patients for treatment, with sicker patients receiving treatment first (ICER,  
17  
18 2014c). They felt this was reasonable not only because the short-term clinical risks  
19  
20 were minimal, but because there was inadequate infrastructure to treat all patients  
21 immediately and because the financial repercussions of immediate treatment for all  
22  
23 eligible patients was unrealistic (ICER, 2014c).  
24

25 The recommendation to use severity of initial liver damage as a method of  
26 prioritizing patients was the recommendation that was included in the final CEPAC  
27  
28 report (ICER, 2014). The patient advocacy organizations did not accept this  
29  
30 recommendation and opposed it in the press (Clary, 2015). But private and  
31 public health insurers felt empowered to establish their initial coverage  
32  
33 recommendations to mirror this approach, and many cited the CEPAC report as  
34  
35 justification (e.g. UnitedHealthcare, 2014). Anecdotally, many insurers informed the  
36 Institute that having a transparent, independent process for evidence review was  
37  
38 important to their decision-making. Even if patient advocacy groups disagreed with  
39  
40 the result, insurers felt that the overall process had enough legitimacy to serve as a  
41  
42 cornerstone of their coverage policies.

43 The case underlines complex questions about the purpose of PPI and the  
44  
45 legitimacy of prioritization decisions. While insurers found the Institute's process  
46 helpful, the protests by patient advocacy groups suggest that they did not view the  
47  
48 CEPAC vote as a fair outcome of a legitimate process. The extant literature on the  
49  
50 legitimacy of decision-making processes in health priority-setting converges on the  
51 idea that outcomes of decisions are more legitimate if the public has been involved  
52  
53 (Daniels and Sabin, 1997; Abelson et al., 2007; Parkinson, 2003). However, the  
54

55  
56 <sup>3</sup> Please note that this section is an account from one of the co-authors who is the Director of  
57 the Institute and was present in the deliberations. The full summary of the proceedings can be  
58 found on the Institute's website (ICER, 2015).



1  
2  
3 experience of the Institute for Clinical and Economic Review in the case of HCV  
4  
5 medicines suggests that enhancing the legitimacy of decision-making processes of  
6 independent review bodies in the eyes of public and patient representatives remains a  
7  
8 challenging issue.  
9

## 10 **Discussion and Conclusion**

11

12  
13  
14  
15 Examining PPI in the case of sofosbuvir across multiple and diverse settings  
16 highlights that none of the countries included in this paper diverted from their  
17  
18 established modes of involving the public and patients. These modes need to be  
19  
20 viewed in the political and historical contexts of the respective countries. They led to  
21 different, yet very important, questions that need to be addressed. In England,  
22  
23 stakeholders stressed the controversies that arise when cost effective medicines are  
24  
25 not covered within the statutory timeframe due to budget impact concerns, even  
26 though such a delay is statutorily permitted in certain circumstances. This suggests  
27  
28 that the methodological approach employed by NICE does not sit easily with  
29  
30 stakeholders. The public consultation process highlighted this issue, but it cannot be  
31 resolved in the currently available PPI forums. It is a political question that needs to  
32  
33 be addressed in the wider public space.  
34

35 In South Korea, a scandal pre-empted potential deliberations by the  
36 established Citizen Committee of Participation. The Korean example brings to the  
37  
38 forefront the importance of what Slutsky et al. (2016) label ‘contestatory  
39  
40 participation’ and of the significant pressure that media campaigns can exert on  
41 decision-making in health priority-setting. It remains to be seen how the story  
42  
43 unfolds, but it seems likely that the established forums of PPI will not deviate from  
44  
45 the public perception that the novel HCV medicines should be made available in the  
46 light of unethical medical practices. The Korean example is as much a story of  
47  
48 successful pressure exerted through media spaces as it is an example of how an issue  
49  
50 can reach the policy agenda and exacerbate the challenges faced by policymakers.

51 The experiences of the USA and Brazil countries underline the importance of  
52  
53 national context. The deliberative meetings held by the Institute for Clinical and  
54  
55 Economic Review fill a void in a fragmented health system in which insurers, the  
56 public and patient advocacy groups have little guidance on which to draw when  
57  
58 making tough decisions or engaging with each other. The Institute’s experience

1  
2  
3 accentuates the role that deliberative processes can play in evaluating evidence.  
4  
5 However, it also shows how challenging it is for these processes to be viewed as  
6 legitimate by all those involved (Kieslich and Littlejohns, 2015), and failing to  
7  
8 establish legitimacy is a real barrier to the contribution that public participation  
9  
10 activities can make. In Latin America, PPI takes places in the context of national  
11 health systems that guarantee a right to health. The public and the patients insist on  
12  
13 their right to health and policymakers are faced with the constraints that this system  
14  
15 puts on policies that seek to introduce efficiency savings.

16 In conclusion, has the PPI experience in Brazil, England, South Korea and the  
17  
18 USA helped address some of the difficult challenges that arise in the case of  
19  
20 sofosbuvir? The short answer is no. The country experiences are as much a tale of  
21 challenges that arise when making difficult prioritization decisions as they are a tale  
22  
23 of agenda-setting. With regard to the unconventional modes of participation such as  
24  
25 protests and litigation, this observation is not surprising as they tend to receive much  
26 attention in the media. However, with regard to the more conventional modes of  
27  
28 participation through consultation and deliberation, this observation is interesting as it  
29  
30 may suggest an agenda-setting role for the public even when this is not the explicit  
31 purpose of these modes of participation. PPI on sofosbuvir has brought a number of  
32  
33 issues to, or back on, the policy agenda. In England, policymakers need to address  
34  
35 what NICE's cost effective paradigm implies for a cash-strapped NHS. The American  
36 experience suggests it may be time for policymakers to think about how they can help  
37  
38 insurers and providers establish decision-making processes that are perceived as  
39  
40 legitimate by the public. In South Korea, the importance of combining ethical and  
41 budgetary considerations has been underlined, especially when patients are infected  
42  
43 with HCV through no fault of their own. In Latin America policymakers are having to  
44  
45 strike the balance between realizing the right to health and the necessity to ensure the  
46 sustainability of health care systems (Ferraz, 2011). Of course, whether these issues  
47  
48 find traction on the policy agenda depends on the receptiveness and willingness of  
49  
50 policymakers to engage with them, and this question is an area for further research.

51 The possible role of issue characteristics (Lowi, 1964; Burgin, 1995) also  
52  
53 merits attention in future research. Lowi (1964) argues that variations in policy-  
54  
55 making processes can be explained with reference to the character and type of issues  
56 that are being addressed. In the case of pharmaceutical products issue characteristics  
57  
58 include the disease area, the population affected, cost effectiveness, budget impact

1  
2  
3 and questions of equity. The question that demands further exploration is whether  
4  
5 certain characteristics of issues brought forth by cases such as the new HCV  
6 medicines call for a stronger, or a particular mode of public involvement. Given its  
7  
8 large budget impact, views from the wider public could be gained on the kind of  
9  
10 trade-offs they would be willing to make if access to the new hepatitis C medicines is  
11 to be provided. However, constructing a case for a stronger, or a particular mode of  
12 public involvement, will rest on the resolution of at least three arguments against it.  
13  
14

15 First, the discussed issues are not new or unique to HCV medicines. They are  
16 simply more pronounced in this case. The novel HCV drugs have brought to light the  
17  
18 challenging issues that have long concerned policymakers, practitioners and  
19  
20 academics. To use these challenges as an argument for going beyond existing modes  
21 of PPI would run the risk of establishing a case of exceptionality that may not be  
22 justified. Second, existing modes of involvement or participation all come with their  
23  
24 own advantages, disadvantages and risks (Weale et al., 2016). Regardless of how  
25 carefully a particular mode of involvement is chosen, chances are that none of them  
26  
27 can address the entire breadth of issues. Third, isolating the situations in which issue  
28  
29 characteristics exacerbate the challenges of decision-making to such an extent that  
30 warrants for taking the issues to the public at large would be difficult. Nevertheless,  
31  
32 the complex trade-offs emerging in priority-setting decisions on HCV medicines  
33  
34 suggest that the normative and empirical role of issue characteristics is worth  
35  
36 exploring.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

## References

Abelson, J., Eyles, J., McLeod, CB, Collins, P., McMullan, C. and Forest, PG. (2003), "Does deliberation make a difference? Results from a citizens panel study of health goals priority setting", *Health Policy*, Vol. 66 No. 1, pp. 95-106.

Abelson, J., Giacomini, M., Lehoux, P. and Gauvin, FP. (2007), "Bringing 'the public' into health technology assessment and coverage policy decisions: From principles to practice", *Health Policy*, Vol. 82 No. 1, pp. 37-50.

Ah-young, Chung. (2015), "Dana Clinic under probe for medical misconduct", The Korea Times, available at: [http://www.koreatimes.co.kr/www/news/nation/2015/12/116\\_192346.html](http://www.koreatimes.co.kr/www/news/nation/2015/12/116_192346.html) (accessed 19 January 2016).

Ah-young, Chung. (2015a). "Hepatitis C patients seek class action against clinic", The Korea Times, available at: [http://koreatimes.co.kr/www/news/nation/2015/12/113\\_192728.html](http://koreatimes.co.kr/www/news/nation/2015/12/113_192728.html) (accessed 19 January 2016).

Ahn, J., Kim, G., Sun Suh, H. and Moo Lee, S. (2012), "Social values and healthcare priority-setting in Korea", *Journal of Health Organization and Management*, Vol. 26 No. 3, pp. 343-350.

Bagcchi, S. (2015), "Campaigners challenge patent applications for hepatitis C drug in five countries", *BMJ* 2015;350:h2938. doi: <http://dx.doi.org/10.1136/bmj.h2938>

Boseley, S. (2015), "Doctors challenge hepatitis C drug patent in price protest", The Guardian, available at: <http://www.theguardian.com/society/2015/feb/10/doctors-hepatitis-c-drug-patent-price-protest> (accessed 17 January 2016).

Brazilian Movement of the Fight against Viral Hepatitis (MBHV) [in Portuguese]. (2015) "Novos Horizontes, Novas Respostas Para Quem?", available at: <http://www.mbhv.org/Manifesto%20hep%20C%20Jo%20C3%A3o%20Pessoa.pdf> (accessed 03 March 2016).

Burgin, E. (1995), "Representatives' Involvement in Foreign and Defense Policy Issues: Do Issue Characteristics Affect Participation?", *Congress & the Presidency*, Vol. 22 No. 1, pp. 57-84.

Clark, S. and Weale, A. (2012), "Social values in health priority setting: a conceptual framework", *Journal of Health Organization and Management*, Vol. 26 No. 3, pp. 293-316.

Clary, R. (2015). A Time to Cure: The Growing Case for New Hepatitis C Treatments. *The Huffington Post*, available at:

1  
2  
3 [http://www.huffingtonpost.com/ryan-clary/a-time-to-cure-the-growing-case-for-](http://www.huffingtonpost.com/ryan-clary/a-time-to-cure-the-growing-case-for-new-hepatitis-c-treatments_b_7976444.html)  
4 [new-hepatitis-c-treatments\\_b\\_7976444.html](http://www.huffingtonpost.com/ryan-clary/a-time-to-cure-the-growing-case-for-new-hepatitis-c-treatments_b_7976444.html) (accessed 03 March 2016).

5  
6 Claxton, K., Sculpher, M., Palmer, S. and Culyer, A.J. (2015), “Causes for  
7 concern: Is NICE failing to uphold its responsibilities to all NHS patients?”,  
8 *Health Economics*, Vol. 24 No. 1, pp. 1-7.  
9

10  
11 Comissão Nacional de Incorporação de Tecnologias no SUS (CONITEC) [in  
12 Portuguese]. (2015), “Simeprevir, sofosbuvir, e daclastavir no tratamento da  
13 Hepatite Crônica tipo C e coinfeccões”, available at:  
14 [http://conitec.gov.br/images/Consultas/Relatorios/2015/Relatorio\\_Antivirais\\_HC](http://conitec.gov.br/images/Consultas/Relatorios/2015/Relatorio_Antivirais_HC_V_CP.pdf)  
15 [V\\_CP.pdf](http://conitec.gov.br/images/Consultas/Relatorios/2015/Relatorio_Antivirais_HC_V_CP.pdf) (accessed 02 February 2016).  
16  
17

18 Cubillos, L., Escobar, M.L. and Iunes, R. (2012), “Universal Health and Litigation  
19 in Latin America”, *Journal of Health Organization and Management*, Vol. 26 No.  
20 3, pp. 390-406.  
21

22 Daniels, N. and Sabin, J. (1997), “Limits to health care: fair procedures,  
23 democratic deliberation, and the legitimacy problem for insurers”, *Philosophy &*  
24 *Public Affairs*, Vol. 26 No. 4, pp. 303–350.  
25

26 Dall’Agnol Modesto, A.A., Costa, A. and Bahia L. (2007) “Health and Social  
27 Determinants in Brazil: A Study on the Influence of Public Participation on the  
28 Formulation of the Expanded Concept of Health and Liberating Practices”, *World*  
29 *Health Organization*, available at:  
30 [http://www.who.int/social\\_determinants/resources/isa\\_public\\_participation\\_bra.p](http://www.who.int/social_determinants/resources/isa_public_participation_bra.pdf)  
31 [df](http://www.who.int/social_determinants/resources/isa_public_participation_bra.pdf) (accessed 03 March 2016).  
32  
33

34 Emanuel, E. (2002), “Book Review of Setting Limits Fairly: Can We Learn to  
35 Share Medical Resources?” *New England Journal of Medicine*, Vol. 347 No. 12,  
36 pp. 953–954.  
37

38 European Medicines Agency. (2015), “Sovaldi (sofosbuvir)”, available at:  
39 [http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002798/human_med_001723.jsp&mid=WC0b01ac058001d124)  
40 [/002798/human\\_med\\_001723.jsp&mid=WC0b01ac058001d124](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002798/human_med_001723.jsp&mid=WC0b01ac058001d124) (accessed 12  
41 January 2016).  
42  
43

44 Ferraz, O.L. (2011) “Brazil – Health Inequalities, Rights, and the Courts: The  
45 Social Impact of the Judicialization of Health”, in Yamin, A.E. and Gloppen, S.  
46 (eds.), *Litigating Health Rights – Can Courts Bring more Justice to Health?*,  
47 Harvard University Press, Cambridge, pp. 76-103.  
48  
49

50 Friedman, A. (2008), “Beyond Accountability for Reasonableness”, *Bioethics*,  
51 Vol. 22 No. 2, pp. 101–112.  
52

53 Goold, S.D., Biddle, A.K., Klipp, G., Hall, C.N. and Danis, M. (2005), “Choosing  
54 Healthplans All Together: A Deliberative Exercise for Allocating Limited Health  
55 Care Resources”, *Journal of Health Politics, Policy and Law*, Vol. 30 No. 4, pp.  
56 563-603.

Graham, C. and Swan, T. (2015), “A path to eradication of hepatitis C in low- and middle-income countries”, *Antiviral Research*, Vol. 119, pp. 89-96.

Institute for Clinical and Economic Review (ICER). (2014), “The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection - A Technology Assessment (Final Report)”, available at:  
[http://ctaf.org/sites/default/files/assessments/CTAF\\_Hep\\_C\\_Apr14\\_final.pdf](http://ctaf.org/sites/default/files/assessments/CTAF_Hep_C_Apr14_final.pdf) (accessed 02 March 2016).

Institute for Clinical and Economic Review (ICER). (2014a), “The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection - Summary of Public Comments and Response on Draft Report”, available at:  
[http://ctaf.org/sites/default/files/u119/Response\\_to\\_Comments\\_HepC\\_041514.pdf](http://ctaf.org/sites/default/files/u119/Response_to_Comments_HepC_041514.pdf) (accessed 02 March 2016).

Institute for Clinical and Economic Review (ICER). (2014b), “California Technology Assessment Forum - New Treatments for Hepatitis C - March 10, 2014 - Voting Questions and Results”, available at:  
[http://ctaf.org/sites/default/files/u119/CTAF\\_HepC\\_voting\\_questions\\_and\\_responses\\_posted\\_0.pdf](http://ctaf.org/sites/default/files/u119/CTAF_HepC_voting_questions_and_responses_posted_0.pdf) (accessed 02 March 2016).

Institute for Clinical and Economic Review (ICER). (2014c), “Video of afternoon session 2 (Policy roundtable part 2)”, available at:  
[https://www.youtube.com/watch?v=G76\\_Wv6IwfU&feature=youtu.be](https://www.youtube.com/watch?v=G76_Wv6IwfU&feature=youtu.be) (accessed 02 March 2016).

Institute for Clinical and Economic Review (ICER). (2015), “California Technology Assessment Forum – Treatments for Hepatitis C”, available at:  
<http://ctaf.org/reports/treatments-hepatitis-c> (accessed 02 March 2016).

Institute for Clinical and Economic Review (ICER). (2016), “About CEPAC”, available at: <http://cepac.icer-review.org/about-cepac2/> (accessed 02 March 2016).

Kapiriri, L. and Martin, DK. (2010), “Successful Priority Setting in Low and Middle Income Countries: A Framework for Evaluation”, *Health Care Analysis*, Vol. 18. No. 2, pp. 129-147.

Kieslich, K. and Littlejohns, P. (2015), “Does accountability for reasonableness work? A protocol for a mixed methods study using an audit tool to evaluate the decision-making of clinical commissioning groups in England”, *BMJ Open*, 5:e007908. doi:10.1136/bmjopen-2015-007908

Lowi, TJ. (1964), “American Business, Public Policy, Case-Studies and Political Theory”, *World Politics*, Vol. 16 No. 4, pp. 677-715.

Martin, D., Abelson, J. and Singer, P. (2002), “Participation in health care priority-setting through the eyes of the participants”, *Journal of Health Services Research & Policy*, Vol. 7 No. 4, pp. 222-229.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

McCarthy, M. (2014), “Treat sickest hepatitis C patients first, new US guidelines recommend”, *BMJ* 2014;349:g5163. doi: <http://dx.doi.org/10.1136/bmj.g5163>

McCarthy, M. (2015), “Hepatitis C drug maker puts profit ahead of patients, US Senate report charges”, *BMJ* 2015;351:h6573. doi: <http://dx.doi.org/10.1136/bmj.h6573>

Ministerio de Salud de Colombia [in Spanish]. (2015), “Estudio de Suficiencia de la UPC y del POS”, available at: <https://www.minsalud.gov.co/salud/POS/mi-plan/Paginas/upc-informacion-para-EPS-IPS.aspx> (accessed on 02 February 2016).

Mitton, C., Smith, N., Peacock, S., Evoy, B., and Abelson, J. (2009), “Public participation in health care priority setting: A scoping review”, *Health Policy*, Vol. 91 No. 3, pp. 219-228.

National Institute for Health and Care Excellence. (2013), “Single Technology Appraisal (STA) Sofosbuvir for treating chronic hepatitis C [ID654] Matrix of consultees and commentators”, available at: <https://www.nice.org.uk/guidance/TA330/documents/hepatitis-c-chronic-sofosbuvir-final-matrix2> (accessed 15 January 2016).

National Institute for Health and Care Excellence. (2014), “Sofosbuvir for treating chronic hepatitis C - Response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)”, available at: <https://www.nice.org.uk/guidance/gid-cgwave0666/resources/hepatitis-c-chronic-sofosbuvir-id654-committee-papers2> (accessed 15 January 2016).

National Institute for Health and Care Excellence. (2014a), “NICE appraisal of sofosbuvir for treating chronic hepatitis C - Consideration of the case for extending the period before funding needs to be made available for a NICE technology appraisal”, available at: <https://www.nice.org.uk/guidance/gid-cgwave0666/resources/hepatitis-c-chronic-sofosbuvir-id654-committee-papers2> (accessed 15 January 2016).

National Institute for Health and Care Excellence. (2014b), “Hepatitis C (chronic) – sofosbuvir [ID654]: committee papers”, available at: <https://www.nice.org.uk/guidance/gid-cgwave0666/resources/hepatitis-c-chronic-sofosbuvir-id654-committee-papers2> (accessed 15 January 2016).

National Institute for Health and Care Excellence. (2015), “Sofosbuvir for treating chronic hepatitis C”, available at: <https://www.nice.org.uk/guidance/ta330/resources/sofosbuvir-for-treating-chronic-hepatitisc-82602540657349> (accessed 12 January 2016).

National Institute for Health and Care Excellence. (2016), “NICE guidance”, available at: <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance> (accessed 15 January 2016).

1  
2  
3 National Institute for Health and Care Excellence. (2016a), “Public involvement”,  
4 available at: <https://www.nice.org.uk/about/nice-communities/public-involvement>  
5 (accessed 15 January 2016).  
6

7 NHS Choices. (2015), “Hepatitis C”, available at:  
8 <http://www.nhs.uk/conditions/Hepatitis-C/pages/introduction.aspx> (accessed 12  
9 January 2016).  
10

11 NHS England. (2016), “About NHS England”, available at:  
12 <https://www.england.nhs.uk/about/> (accessed 15 January 2016).  
13  
14

15 Oh, J., Young, K, Baer Alley, A. and Kwon, S. (2015), “Participation of the Lay  
16 Public in Decision-Making for Benefit Coverage of National Health Insurance in  
17 South Korea”, *Health Systems & Reform*, Vol. 1 No. 1, pp. 62-71.  
18  
19

20 Organisation for Economic Co-operation and Development (OECD). (2012),  
21 “Measuring health coverage”, available at: [http://www.oecd.org/els/health-](http://www.oecd.org/els/health-systems/measuring-health-coverage.htm)  
22 [systems/measuring-health-coverage.htm](http://www.oecd.org/els/health-systems/measuring-health-coverage.htm) (accessed 05 March 2016).  
23

24 Organisation for Economic Co-operation and Development (OECD). (2015),  
25 “OECD Health Statistics 2015”, available at:  
26 <http://stats.oecd.org/Index.aspx?DataSetCode=SHA> (accessed 05 March 2016).  
27

28 Paim, J., Travassos, C., Almeida, C., Bahia, L. and Macinko, J. (2011), “The  
29 Brazilian health system: history, advances, and challenges”, *The Lancet*, Vol. 377  
30 No. 9779, pp. 1778–1797  
31  
32

33 Parkinson, J. (2003), “Legitimacy Problems in Deliberative Democracy”, *Political*  
34 *Studies*, Vol. 51, pp. 180-196.  
35

36 PCDT Relatório 171 Para hepatite c viral crônica - Nº 37/2015 - Publicada em  
37 27/07/2015  
38  
39

40 Rid, A. (2009), “Justice and Procedure: How Does ‘Accountability for  
41 Reasonableness’ Result in Fair Limit-Setting Decisions?” *Journal of Medical*  
42 *Ethics*, Vol. 35 No. 1, pp. 12–16.  
43

44 Rid, A., Littlejohns, P., Wilson, J., Rumbold, B., Kieslich, K. and Weale, A.  
45 (2015), “The importance of being NICE”, *Journal of the Royal Society of*  
46 *Medicine*, Vol. 108 No. 10, pp. 385-389.  
47

48 Sabik, LM. and Lie, RK. (2008), “Principles versus Procedures in Making Health  
49 Care Coverage Decisions: Addressing Inevitable Conflicts”, *Theoretical Medicine*  
50 *and Bioethics*, Vol. 29 No. 2, pp. 73–85.  
51  
52

53 Seong, MH, Kil, H, Kim, JY, Lee, SS, Jang, ES, Kim, JW, et al. (2013), “Clinical  
54 and epidemiological characteristics of Korean patients with hepatitis C virus  
55 genotype 6”, *Clinical and Molecular Hepatology*, Vol. 19, pp. 45-50.



Sibbald, SL., Singer, PA., Upshur, R. and Martin, DK. (2009), "Priority setting: what constitutes success? A conceptual framework for successful priority setting", *BMC Health Services Research*, Vol. 9 No. 43, pp.?

Slutsky, J., Tumilty, E., Max, C., Lu, L., Tantivess, S., Hauengen, RC., Whitty, JA, Weale, A., Pearson, S., Tugendhaft, A., Wang, H., Staniszewska, S., Weerasuriya, K., Ahn, J. and Cubillos, L. (2016), "Patterns of Public Participation: Opportunity Structures and Mobilization from a Cross-National Perspective", *Journal of Health Organization and Management*, This issue.

The Commonwealth Fund. (2015), "The U.S. Health Care System, 2014", in Mossialos, E., Wenzl, M., Osborn, R. and Anderson, C. (eds.), *2014 International Profiles of Health Care Systems*, The Commonwealth Fund, New York, pp. 153-162.

The DailyPharm [in Korean]. (2015), available at: <http://www.dailypharm.com/News/207661> (accessed 18 January 2016).

The Hepatitis C Trust. (2014), "NICE appraisal of sofosbuvir for treating chronic hepatitis C - Consideration of the case for extending the period before funding needs to be made available for a NICE technology appraisal", available at: <https://www.nice.org.uk/guidance/gid-cgwave0666/resources/hepatitis-c-chronic-sofosbuvir-id654-committee-papers2> (accessed 15 January 2016).

The Korean Ministry of Food and Drug Safety Online Pharmaceutical Library [in Korean]. (2015), available at: [http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item\\_Seq=201506496](http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201506496) (accessed 18 January 2016).

The Korean Ministry of Food and Drug Safety Online Pharmaceutical Library [in Korean]. (2015), available at: [http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item\\_Seq=201507122](http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201507122) (accessed 18 January 2016).

Thorlby, R. and Arora, S. (2015), "The English Health Care System, 2014", in Mossialos, E., Wenzl, M., Osborn, R. and Anderson, C. (eds.), *2014 International Profiles of Health Care Systems*, The Commonwealth Fund, New York, pp. 43-52.

UnitedHealthcare. (2014), "Prior Authorization/Medical Necessity - Harvoni™ (ledipasvir/sofosbuvir)", available at: [https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%20Resources/Pharmacy%20Resources/Harvoni\\_Medical\\_Necessity.PDF](https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%20Resources/Pharmacy%20Resources/Harvoni_Medical_Necessity.PDF) (accessed 03 March 2016).

U.S. Food and Drug Administration. (2014), "Approval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C", available at: <http://www.fda.gov/forpatients/illness/hepatitisbc/ucm377920.htm> (accessed 12 January 2016).

1  
2  
3  
4 Vietri, J, Prajapati, G. and El Khoury, AC. (2013), “The burden of hepatitis C in  
5 Europe from the patients’ perspective: a survey in 5 countries”, *BMC*  
6 *Gastroenterology*, Vol. 13 No. 1, pp. 1-8.  
7

8  
9 Ward, A. (2015), Expensive drugs cost lives, claims report. *The Financial Times*,  
10 available at: [http://www.ft.com/cms/s/0/d00c4a02-b784-11e4-981d-](http://www.ft.com/cms/s/0/d00c4a02-b784-11e4-981d-00144feab7de.html#axzz48FRm09Xb)  
11 [00144feab7de.html#axzz48FRm09Xb](http://www.ft.com/cms/s/0/d00c4a02-b784-11e4-981d-00144feab7de.html#axzz48FRm09Xb) (accessed 19 May 2016).  
12

13 Weale, A., Kieslich, K., Littlejohns, P., Tugendhaft, A., Tumilty, E. and Whitty,  
14 J.A. (2016), “Introduction: Priority Setting, Equitable Access and Public  
15 Involvement in Health Care”, *Journal of Health Organization and Management*,  
16 This issue.  
17

18  
19 Work Group of Intellectual Property (GTPI) [in Portuguese]. (2015), “Carta  
20 aberta do GTPI ao movimento de luta contra as hepatites virais e a todas as  
21 pessoas vivendo e convivendo com a doença”, [online] available at:  
22 [http://www.deolhonaspateentes.org.br/blog/blog/carta\\_aberta\\_do\\_gtpi\\_ao\\_movime](http://www.deolhonaspateentes.org.br/blog/blog/carta_aberta_do_gtpi_ao_movimento_de_luta_contra_as_hepatites_virais_e_a_todas_as_pessoas_vivendo_e_convivendo_com_a_doenca.html#_ftn2)  
23 [nto\\_de\\_luta\\_contra\\_as\\_hepatites\\_virais\\_e\\_a\\_todas\\_as\\_pessoas\\_vivendo\\_e\\_convi](http://www.deolhonaspateentes.org.br/blog/blog/carta_aberta_do_gtpi_ao_movimento_de_luta_contra_as_hepatites_virais_e_a_todas_as_pessoas_vivendo_e_convivendo_com_a_doenca.html#_ftn2)  
24 [vendo\\_com\\_a\\_doenca.html#\\_ftn2](http://www.deolhonaspateentes.org.br/blog/blog/carta_aberta_do_gtpi_ao_movimento_de_luta_contra_as_hepatites_virais_e_a_todas_as_pessoas_vivendo_e_convivendo_com_a_doenca.html#_ftn2) (accessed 03 March 2016).  
25

26  
27 World Health Organization. (2014), “Guidelines for the screening, care and  
28 treatment of persons with hepatitis C infection”, [online] available at:  
29 [http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755\\_eng.pdf?ua=1](http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf?ua=1&ua=1)  
30 [&ua=1](http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf?ua=1&ua=1) (accessed 12 January 2016).  
31

32 Younossi, Z. and Henry, L. (2015), “Systematic review: patient-reported  
33 outcomes in chronic hepatitis C - the impact of liver disease and new treatment  
34 regimens”, *Alimentary Pharmacology & Therapeutics*, Vol. 41 No. 6, pp. 497-  
35 520.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55